... are obstructed by large blood clots. Clinical diagnosis: fatal PE. PE, pulmonary embolism. The relative frequencies of TEEs in various subgroups are listed in Table  2 . By far, the highest frequency of 40.5% was found in patients with CVA. A rate of 19.2% was observed in patients with cisplatin...

...%) participants were stated to regularly use NAC and AC respectively. The number of participants who were stated to use NAC and AC regularly was not associated with the type of institution (academic vs. nonacademic), number of hospital beds, and number of cystectomies performed annually. Gemcitabine/cisplatin...

... with MIBC treated by trimodal chemoradiotherapy with cisplatin (CDDP-radiation [CDDP-R]). Transurethral resection of the bladder tumor (TURBT) was performed before treatment to confirm pathological stage ≥T2. Extensive TURBT was performed after chemoradiotherapy to evaluate the pathological response...

...Isabel Heidegger; Daniel Porres; Nica Veek; Axel Heidenreich; David Pfister Background: Malignancies and cisplatin-based chemotherapy are both known to correlate with a high risk of venous thrombotic events (VTT). In testicular cancer, the information regarding the incidence and reason of VTT...

... cancer patients undergoing cisplatin-based chemotherapy. Patients and Methods: LMWH prophylaxis was given from the first day of chemotherapy until 21 days after completing the last chemotherapy cycle to 45 out of 93 (48.4%) patients (extended), and to 48 out of 93 (51.6%) patients during...

..., but developed pulmonary metastatic disease 7 months postoperatively. Six cycles of gemcitabine/cisplatin combination chemotherapy with an addition of gefitinib as daily oral medication were administered within a randomized phase II clinical trial; this resulted in complete remission of the pulmonary metastases...

.... Methods: Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m 2 on days 1 and 8, and cisplatin 70 mg/m 2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential...

... of spermatogenesis in testicular cancer patients following chemotherapy. Patients and Methods: 49 patients, consisting of 45 treated with a bleomycin, etoposide and cisplatin (BEP) regimen and 4 with high-dose chemotherapy, were followed up with occasional semen analyses. The primary endpoint of this study...

...İ. Deǧ;irmenci; A. Başaran; K. Erol; E. Açikalin; H.V. Güneş; S. Yazıcıoǧ;lu; A.G. Tomatír; H. Gün In the present study, some toxic effects of cisplatin are evaluated in rats. It was also investigated whether S-carboxymethylcysteine (S-CMC), a free radical scavenger, protects the experimental...

...M. Matsushima; T. Tajima; T. Kase; M. Harada; M. Takanami; T. Yagishita; Y. Sawamura; M. Shirai; I. Kaneko; K. Kuwashima; N. Nakayama; R. Suzuki Since September 1985, 44 patients with advanced urinary bladder cancer have been treated by combined cisplatin and full-dose radiotherapy. The patients...

...M. Takashi; Y. Zhu; K. Miyake; K. Kato Calbindin-D, a vitamin D-dependent calcium-binding protein of 28 kD, is found predominantly in the distal tubules of the kidney and central nervous system tissues in humans. To evaluate damage to the renal tubules caused by cisplatin-based chemotherapy, levels...

... months after the second treatment, multiple lung metastasis and a second local recurrence in the inguinal skin were found. High-dose chemotherapy with cisplatin and doxorubicin was performed, but no change was confirmed after 4 weeks. The disease progressed, resulting in death within 8 months...

...Jiro Uozumi; Toyofumi Ueda; Tetsuo Yasumasu; Yasuhiro Koikawa; Seiji Naito; Joichi Kumazawa; Toshiharu Kamura; Hitoo Nakano; Katsuo Sueishi To evaluate the effects of repeated administration of cisplatin on kidney platinum (Pt) accumulation and renal function, Pt content in the kidney...

...Mikio Igawa; Hitoshi Kadena; Takatoshi Tacho; Takahisa Nakamoto; Tsuguru Usui Thirty-seven patients with urothelial cancer were given combination chemotherapy with methotrexate, etoposide and cisplatin. Thirty patients were evaluated for response. Response rates were 50% in the primary organ, 50...

...U. Engelmann; J. Krug; W. Sonntag; G.H. Jacobi The influence of a single dose cisplatin on wound healing of enterostomies in rats was investigated by measurement of the wound-breaking strength, microangiographically and histologically. Cisplatin (5 mg/kg body weight) was given on day ––1 or day ––5...

.... The combination effect of rAAV-wt-p53 and cisplatin was measured by MTT assay. Results: The virus rAAV efficiently enters the cells and expresses its gene products. The gene product of rAAV-wt-p53 is cytotoxic to bladder cancer cells. The bladder cell line 5637 was found to experience a synergistic killing effect...

...Meltem Ozlen Dillioglugil; Hale Maral Kir; Mehmet Dogan Gulkac; Aylin Özon Kanli; Hacı Kahya Ozdogan; Oguz Acar; Ozdal Dillioglugil Objective: Cisplatin (DDP, cis -diamminedichloroplatinium II) is one of the most potent chemotherapeutic antitumor drugs, but is able to generate reactive oxygen...

...Enrico Meliani; Alberto Lapini; Sergio Serni; Cristoforo Corvino; Marco Carini Objective: To evaluate the toxicity of gemcitabine and cisplatin combination therapy in adjuvant regimen after radical cystectomy for muscle invasive bladder cancer. Patients and Methods: Forty patients underwent radical...

... were scheduled for 4 cycles of bleomycin-etoposide-cisplatin (BEP) or methotrexate-vinblastine-etoposide-cisplatin (MVEC) combination chemotherapy, respectively. At each cycle the whole cisplatin dose was given in 1 day that is 100 mg/m 2 /day in the BEP and 70 mg/m 2 /day in the MVEC protocols...